Table 2.

Primary locoregional and systemic treatment received by all patients according to insurance type by stage

All patients, n (%)Public, n (%)Private, n (%)
N = 3,142N = 2,155N = 987P
Breast surgery (any)2,551 (85)1,728 (84)823 (86)0.035
 Mastectomya1,582 (62)1,170 (68)412 (50)<0.001g
 Lumpectomya956 (38)550 (32)406 (49)
 Type unknowna13 (1)8 (1)5 (1)
Sentinel lymph node biopsyb478 (19)267 (15)211 (26)<0.001
Complete axillary dissectionb2,014 (79)1,449 (84)565 (69)<0.001
Postoperative radiotherapy1,912 (61)1,304 (61)608 (62)0.582
Chemotherapyc,d2,163 (69)1,513 (70)650 (66)0.015
Endocrine therapyd,e1,077 (86)684 (87)393 (86)0.521
Trastuzumabd,f67 (30)10 (9)57 (53)<0.001

NOTE: P values are for comparison of public and private.

  • aPercentages are calculated by the number of patients in each cell relative to the number of patients that have undergone any surgery.

  • bPercentages use number of patients with any surgery as the denominator.

  • cPercentages are calculated by the number of patients in each cell relative to the total number of patients in each group.

  • dChemotherapy, endocrine therapy, and trastuzumab include adjuvant therapy for stages 0–III or first-line therapy for stage IV.

  • ePercentages are calculated by the number of patients in each cell relative to the number of hormone receptor–positive patients of each group shown in Table 1 (n = 1,945 for all patients, n = 1,330 for public patients, and n = 615 for private patients).

  • fPercentages are calculated by the number of patients in each cell relative to the number of HER2-positive patients shown for each group in Table 1 (n = 224 for all patients, n = 117 for public patients, n = 107 for private patients).

  • gP value for comparison between number of mastectomies and lumpectomies in each group.